<DOC>
	<DOCNO>NCT01182662</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy mesenchymal stem cell ( MSCs ) derive human umbilical cord/placenta dose 1.0E+6 MSC/kg subject therapy severe aplastic anemia ( SAA ) .</brief_summary>
	<brief_title>Safety Efficacy Study Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells Treat Severe Aplastic Anemia</brief_title>
	<detailed_description>Severe aplastic anemia ( SAA ) condition involve low level red blood cell , white blood cell , platelet without evidence another bone marrow disease . Patients severe aplastic anemia produce blood cell , cause fatigue , easy bruise bleeding , susceptibility infection . In many case , low blood count result autoimmune process . The patient 's immune system damage stem cell bone marrow . Although immune-suppressing drug , corticosteroid , CsA ATG , use treatment SAA , however , many study indicate overall response rate drug le 60 % . Addition , severe side effect immune-suppressing drug also observe . The management SAA patient therefore remain unsatisfactory targeted therapy need . Human MSCs isolate human umbilical cord/placenta show immunosuppressive , stimulating hematopoiesis tissue repair property . This study evaluate safety effectiveness MSC transplantation SAA patient . This study last 2 3 year . Participants randomly assign receive either MSC transplant CsA therapy ( experimental group ) CsA therapy alone ( control group ) . Patients undergo MSC transplant start study Day 0 . After 3 month , patient receive second MSC transplantation . After six twelve month first transplantation , patient evaluate .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>1 . Patient age 18~80 year old plan infuse MSCs . 2 . Standard diagnosis aplastic anemia accord Chinese domestic classification AA 1987 . 3 . Patients must ECOG 0~2 . 4 . No moderate sever organ dysfunction : Ejection fraction &gt; 45 % ; Creatinine &lt; 176 umol/L . 5 . No active severe viral fungus infection . 6 . Each patient must sign write informed consent . 1 . Psychiatric condition would limit informed consent . 2 . HIV positive 3 . Positive Pregnancy Test 4 . Patient enrol another clinical trial study within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bone Marrow Disease</keyword>
	<keyword>Aplastic Anemia</keyword>
	<keyword>Umbilical Cord/placenta-Derived MSC</keyword>
	<keyword>Transplantation</keyword>
</DOC>